RedShift BioAnalytics Names New CEO
RedShift BioAnalytics introduced its first system, the AQS3pro platform, in 2018. The AQS3pro platform performs secondary structural analysis of proteins, enabling insight into drug safety and efficacy and monitoring from development through manufacturing. The system employs the company’s proprietary Microfluidic Modulation Spectroscopy (MMS) for label-free protein characterization based on IR spectroscopy and microfluidics to enable less costly, more […]

